Effects of OP2113 on Myocardial Infarct Size and No Reflow in a Rat Myocardial Ischemia/Reperfusion Model.

Wangde DaiNivea Dias AmoedoJustin PerryBruno Le GrandAurelie BoucardJuan CarrenoLifu ZhaoDavid A BrownRodrigue RossignolRobert A Kloner

Published in: Cardiovascular drugs and therapy (2021)

These results suggest that OP2113 is a promising mitochondrial ROS-modulating agent to reduce no-reflow as well as to reduce myocardial infarct size, especially if it is on board early in the course of the infarction. It appears to have benefit on no-reflow even when administered relatively late in the course of ischemia.

Keyphrases

left ventricular
acute myocardial infarction
oxidative stress
dna damage
cell death
signaling pathway
heart failure
acute coronary syndrome
percutaneous coronary intervention
atrial fibrillation